These findings are consistent with our previous studies demonstrating superior regulatory abilities of SOD3-MSCs on T-cell subsets and MCs, as well as improved therapeutic efficacy against psoriasis and atopic dermatitis [13,26]. The gene discussed is SOD3; the disease is atopic eczema.